XML 11 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document And Entity Information - shares
 12 Months Ended
Dec. 31, 2015
Feb. 22, 2016
Document Information [Line Items]    
Entity Registrant Name Protagenic Therapeutics, Inc.\new  
Entity Central Index Key 0001022899  
Trading Symbol atrn  
Current Fiscal Year End Date --06-30  
Entity Filer Category Smaller Reporting Company  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Entity Common Stock, Shares Outstanding (in shares)   400,000,000
Document Type 8-K/A  
Document Period End Date Dec. 31, 2015  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus FY  
Amendment Flag true  
Amendment Description On February 12, 2016, Atrinsic, Inc. ("Atrinsic" or the "Company") filed with the Securities and Exchange Commission (the "SEC") its original Current Report on Form 8-K (the "Original Form 8-K") to report certain events, described in detail therein, including, among other things (1) the completion of a reverse merger transaction, (2) the Company's initial closing of a private placement of the Company's securities at $1.25 per share and (3) certain related items and transactions. The purpose of this Amendment No. 1 to Current Report on Form 8-K/A (the "Amended Form 8-K") is to include the audited financial statements for Protagenic Therapeutics, Inc. for the fiscal years ended December 31, 2015 and 2014. On February 12, 2016, Protagenic Acquisition Corp. ("Acquisition Corp."), a wholly-owned subsidiary of Atrinsic, Inc., a Delaware corporation ("Atrinsic"), merged (the "Merger") with and into Protagenic Therapeutics, Inc. a Delaware corporation ("Protagenic"). Protagenic was the surviving corporation of that Merger. As a result of the Merger, Atrinsic acquired the business of Protagenic and will continue the existing business operations of Protagenic as a wholly-owned subsidiary. As used in this Current Report, the terms the "Company", "we," "us," and "our" refer to Atrinsic and its wholly-owned subsidiary Protagenic, after giving effect to the Merger, unless otherwise stated or the context clearly indicates otherwise. The term "Predecessor" refers to Atrinsic, Inc., before giving effect to the Merger; and the term "Protagenic" refers to Protagenic Therapeutics, Inc., before giving effect to the Merger. This Current Report contains summaries of the material terms of various agreements executed in connection with the transactions described herein. The summaries of these agreements are subject to, and are qualified in their entirety by, reference to these agreements, all of which are incorporated herein by reference.